ADVANCING CANCER TREATMENT (EIN 832886283) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2018

Legal Domicile

Principal Officer

PAMELA BROWN

Phone

9729356510

Tax Period

2024-01-01 to 2024-12-31

ADVANCING CANCER TREATMENT, founded in 2018, is a micro nonprofit in the Diseases & Disorders sector that reported $43K in total revenue in fiscal year 2024. Revenue fell 98% from the prior year — a significant decline worth monitoring. Expenses of $824K exceeded revenue, resulting in a 1796% operating deficit.

Mission

ACTS MISSION IS TO MAKE THE WASHINGTON, DC METROPOLITAN AREA A LEADER IN ADVANCING CLINICAL TRIAL ACCRUAL, THUS ACCELERATING IMPROVED CANCER CARE AND TREATMENT.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $0

Program Service Revenue $0

Investment Income $43,476

Other Revenue $0

TOTAL REVENUE $43,476

Expense Breakdown

Grants Paid $348,330

Salaries & Benefits $0

Fundraising Expenses $1,512

Program Expenses $785,629

Other Expenses $476,033

TOTAL EXPENSES $824,363

Year-over-Year Comparison

	2024	2023	Change
Revenue	$43,476	$2,068,192	-1.0%
Expenses	$824,363	$1,260,009	-0.3%
Net Income	$-780,887	$808,183	-2.0%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

N/A

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
OTIS W BRAWLEY MD	DIRECTOR	0.20	Director	$0	$0	$0
ROBERT L GROSSMAN	DIRECTOR	0.20	Director	$0	$0	$0
JEANNY B ARAGON-CHING MD	DIRECTOR	0.20	Director	$0	$0	$0
DONALD L TRUMP MD	DIRECTOR	0.20	Director	$0	$0	$0
ADAM R METWALLI MD	DIRECTOR	0.20	Director	$0	$0	$0
PAMELA BROWN	VICE PRESIDENT, SECRETARY	0.20	Officer Director	$0	$0	$0
DAVID BROWN	PRESIDENT, TREASURER	0.20	Officer Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	$43,476	$824,363	$714,351	$-780,887
2023	$2,068,192	$1,260,009	$1,484,614	$808,183
2022	$3,010,183	$3,103,502	$683,975	$-93,319
2021	$1,500,077	$819,640	$1,177,066	$680,437
2021	$1,500,077	$1,220,509	$1,176,243	$279,568
2020	$1,600,117	$1,173,683	$496,629	$426,434
2019	$604,430	$534,237	$70,195	$70,193

ADVANCING CANCER TREATMENT